Understanding how anti-VEGF injections affect retinal blood flow in diabetic eye disease
Official title: Characterization of vascular responses to intravitreal anti-VEGF injections in diabetic retinopathy
Funded at Icahn School of Medicine at Mount Sinai · NIH-11370546 · Data updated 2026-11-12
This project will use advanced eye imaging to see how anti-VEGF drugs change blood flow in the retina of people with diabetic retinopathy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 1, 2017 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $628,470 |
| NIH project number | 5R01EY027301-08 |
| Project ID | NIH-11370546 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with diabetic retinopathy who are being treated with intravitreal anti-VEGF injections.
✕Less likely to help
Patients not receiving anti-VEGF therapy or those without access to high-resolution retinal imaging may not directly benefit.
What this research studies
This study will follow patients with diabetic retinopathy who receive intravitreal anti-VEGF injections and use two non-invasive imaging tools, AOSLO and OCTA, to visualize tiny blood vessels and perfusion in the retina. The researchers will develop and apply vascular metrics to track subclinical changes over time and compare them to clinical outcomes like vision and progression. The goal is to better understand why current biomarkers sometimes fail to predict treatment response and to improve monitoring of treatment effects for individuals with DR.
Why it matters
Potential benefit: If successful, patients may receive more accurate monitoring of treatment response and potentially improved guidance on anti-VEGF therapy in diabetic retinopathy.
How similar studies have gone: Preliminary work suggests imaging-based vascular metrics can outperform traditional measures in monitoring treatment response.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Chui, Yuen Ping Toco — Icahn School of Medicine at Mount Sinai
- Study coordinator: Chui, Yuen Ping Toco
Related research
Other NIH-funded projects on the same topics.
-
Integrative multi-omics to understand diabetic retinopathy
A doctor-scientist team will study blood markers and genetic signals to see why diabetic retinopathy happens and how it affects Hispanic/Latino people.
-
Smartphone retinal imaging for diabetic eye disease in Egypt
This project uses a low-cost smartphone camera and AI to find signs of diabetic eye damage in adults with diabetes in Egypt.
-
Retinal Cell Loss in Diabetic Retinopathy
This project looks at how mitochondrial problems and a specific kind of cell death called ferroptosis may cause retinal cells to die in people with diabetes-related eye disease.
-
Redox-triggered REDD1 blockers for diabetic retinopathy
A research project tests new ways to stop a stress protein (REDD1) from causing vision problems in people with diabetic retinopathy.
-
Ultrafast eye imaging to detect and track diabetic retinopathy
A doctor-science team is developing ultra-fast eye scans to better see tiny blood vessels in people with diabetic retinopathy, helping catch changes early and guide treatment.
-
Practical device to automatically track abnormal retinal blood vessel growth in diabetic eye disease
A new, easier-to-use imaging device aims to automatically detect and monitor abnormal retinal blood vessel growth in people with diabetic retinopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.